The tenth meeting of the Emergency Committee convened by the WHO Director-General under the International Health Regulations (2005) (IHR) regarding the coronavirus disease (COVID-19) pandemic took place on Thursday 13 January 2022 from 12:00 to 17:00 Geneva time (CEST).
Proceedings of the meeting
Members and Advisors of the Emergency Committee were convened by videoconference.
The Director-General welcomed the Committee members and advisers. He highlighted the challenges posed by the high transmission levels of the SARS CoV-2 Omicron variant of concern (VOC) and the corresponding burden on public health systems and health service delivery. The Director-General emphasized the importance of vulnerable populations in all countries getting timely and equitable access to COVID-19 vaccination. The Director-General encourages all efforts to expand access to and uptake of vaccination, with the expectation that those who have access to vaccines get vaccinated and continued adherence to PHSM. The DG expressed hope that, by working together, the world can bring an end to the acute phase of the COVID-19 pandemic.
Representatives of the Office of Legal Counsel (LEG) and the Department of Compliance, Risk Management, and Ethics (CRE) briefed the members on their roles and responsibilities. The Ethics Officer from CRE provided the members and advisers with an overview of the WHO Declaration of Interests process. The members and advisers were made aware of their individual responsibility to disclose to WHO, in a timely manner, any interests of a personal, professional, financial, intellectual or commercial nature that may give rise to a perceived or direct conflict of interest. They were additionally reminded of their duty to maintain the confidentiality of the meeting discussions and the work of the Committee. Each member who was present was surveyed. No conflicts of interest were identified.
The Secretariat turned the meeting over to the Chair, Professor Didier Houssin. Professor Houssin noted the continuing challenges caused by SARS-CoV-2 nearly two years after the first meeting of this Committee. He reviewed the objectives and agenda of the meeting.
The Secretariat presented on the current status of the COVID-19 pandemic and a vision for how to optimize the 2022 response to the COVID-19 pandemic. The presentation focused on:
the global epidemiological context including an overview of the Omicron VOC;
factors that continue to drive transmission, potential future scenarios which may involve variants that are more or less severe, and challenges posed by the continued evolution of SARS-CoV-2 in animal and human reservoirs;
the status of COVID-19 vaccines and vaccination targets for 2022; and
updates on international traffic and progress on the Temporary Recommendations issued following the 9th meeting of the Emergency Committee.
The Committee discussed key issues including:
challenges and opportunities to harmonize national and global response efforts within the context of the synchronous outbreaks of Omicron VOC, including in relation to international travel;
drivers for emergence of new VOCs as well as differences in the characteristics of Delta and Omicron VOCs and their respective lineages;
the evolution of SARS-CoV-2 testing strategies as well as accessibility and affordability of medical countermeasures;
vaccination strategies and the use of heterologous vaccine combinations;
the challenges to maintain continued community buy-in for public health and social measures after two years of the pandemic and the risk of overly optimistic statements regarding the state of the pandemic;
the increasing levels of threat and concerns about personal safety faced by frontline responders, advisors and leaders of the pandemic response;
the focus of response efforts on a combination of suppression of transmission and mitigation of severe outcomes; and
the need for an on-going integrated One Health approach to SARS-CoV-2 surveillance, research, and response efforts.
The Committee praised South Africa for their rapid identification, and transparent and rapid sharing of information on the Omicron VOC. The Committee was concerned about the reaction of States Parties in implementing blanket travel bans, which are not effective in suppressing international spread (as clearly demonstrated by the Omicron experience), and may discourage transparent and rapid reporting of emerging VOC.
The Committee noted with concern reports of violence against health workers, public health officials, and expert advisors engaged in the COVID-19 response. The Committee condemns these acts that undermine national and global response efforts.
The Committee expressed deep concern that countries not eligible for the COVAX Facility Advance Market Commitment (AMC) are experiencing challenges affording COVID-19 vaccines. In addition, they noted challenges posed by the high prices of certain therapeutics, the lack of equity in access, and limited data availability on cost-effectiveness of these treatments. The Committee urged WHO to continue its work with the pharmaceutical sector to address barriers to access and affordability, by expanding tiered pricing, voluntary license agreements and other approaches to increase access to vaccines, therapeutics, and diagnostic tests for all countries, possibly looking at the Pandemic Influenza Preparedness Framework for guidance.
